Nautilus Biotechnology, Inc.NAUT
What Nautilus Biotechnology, Inc. does.
On June 9, 2021 (the “Closing Date”), Nautilus Biotechnology, Inc., a Delaware corporation (f/k/a ARYA Sciences Acquisition Corp III (“ARYA”)), consummated the business combination (the “Business Combination”) pursuant to the terms of that certain Business Combination Agreement, dated as of February 7, 2021 (the “Business Combination Agreement”), by and among ARYA, Mako Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ARYA (“Mako Merger Sub”), and Nautilus Subsidiary, Inc., a Delaware corporation (f/k/a Nautilus Biotechnology, Inc.) (“Legacy Nautilus”). The Business Combination Agreement provided for, among other things, (i) the domestication of ARYA as a corporation incorporated under the laws of the State of Delaware, upon which ARYA changed its name to “Nautilus Biotechnology, Inc.” (together with its consolidated subsidiary, the “Company” “New Nautilus” or “Nautilus”) and (ii) the merger of Mako Merger Sub with and into Legacy Nautilus (the “Merger”), with Legacy Nautilus as the surviving company in the Merger and, after giving effect to such Merger, Legacy Nautilus becoming a wholly-owned subsidiary of New Nautilus.
Concurrently with the execution of the Business Combination Agreement, ARYA entered into Subscription Agreements (each, a “Subscription Agreement”) with certain investors (each, a “PIPE Investor”), pursuant to which the PIPE Investors subscribed for and purchased, and ARYA issued and sold to the PIPE Investors, on the Closing Date, an aggregate of 20,000,000 shares of common stock of New Nautilus (“Common Stock”) for aggregate gross proceeds of $200,000,000 (the “PIPE Financing”).
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$15.6M | -$50.3M | -$57.9M | -$63.7M | -$70.8M | -$59.0M |
| Free cash flow | -$14.9M | -$41.5M | -$48.1M | -$54.2M | -$61.3M | -$52.0M |
More on NAUT.
- Nautilus Biotechnology, Inc. summary
- Nautilus Biotechnology, Inc. financial statements
- Nautilus Biotechnology, Inc. key metrics
- Nautilus Biotechnology, Inc. health scores and style box
- Nautilus Biotechnology, Inc. earnings
- Nautilus Biotechnology, Inc. dividends
- Nautilus Biotechnology, Inc. valuation
- Nautilus Biotechnology, Inc. ownership and insiders
- Nautilus Biotechnology, Inc. peers
Figures from Nautilus Biotechnology, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.